Results 131 to 140 of about 898,128 (309)

Take one [PDF]

open access: yes, 1985
This item contains two issues of the Take One newsletter: November 8, and 22, 1985Take One was published every two weeks and focused on short news items and announcements "for the people of University Hospital.

core  

Autophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC‐Derived Cortical Organoids

open access: yesAdvanced Science, EarlyView.
A new cerebrocortical organoid model using isogenic hiPSCs with familial Alzheimer's mutations recapitulates key AD features, including amyloid‐beta and phospho‐Tau aggregation, neuronal hyperexcitability, and synapse loss. Single‐cell RNA‐seq reveals aberrant pathways in excitatory and inhibitory neurons.
Sergio R. Labra   +23 more
wiley   +1 more source

European Works Councils and the healthcare sector [PDF]

open access: yes, 2004
Profiles of healthcare companies with European Works Councils and some eligible ...
Lethbridge, Jane
core  

Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity

open access: yesAdvanced Science, EarlyView.
Attaching antibodies against endothelial cell surface proteins redirects the delivery and expression of DNA‐lipid nanoparticles to organs of interest. Our targeted nanoparticles enable organ‐selective DNA expression in the endothelium of the lungs, brain, or spleen, providing a therapeutic platform for dozens of endothelial‐centric diseases.
Nicolas Marzolini   +24 more
wiley   +1 more source

A Simplified Three‐Tailed N‐Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose‐Accumulated mRNA Delivery for Anti‐Obesity Therapy

open access: yesAdvanced Science, EarlyView.
This study develops an mRNA therapy encoding a long‐acting GLP‐1/FGF21 fusion protein. A three‐tailed ionizable lipid engineered three‐component lipid nanoparticle delivers the mRNA to inguinal adipose tissue. In obese mice, this targeted, dual‐hormone treatment potently reduces body weight, fat mass, presenting a localized strategy for metabolic ...
Bin Ma   +10 more
wiley   +1 more source

Barnes Hospital Bulletin [PDF]

open access: yes, 1972
https://digitalcommons.wustl.edu/bjc_barnes_bulletin/1078/thumbnail ...

core   +1 more source

F13A1‐Mediated Macrophage Activation Promotes MASH Progression via the PKM2/HIF1A Pathway

open access: yesAdvanced Science, EarlyView.
In fatty liver disease, hepatocytes exposed to palmitate release S1P, which activates calcium signaling in macrophages. Elevated calcium enhances the activity of F13A1, driving PKM2 dimerization. The PKM2 dimers cause Warburg effect, translocate to the nucleus, cooperate with HIF1A, and upregulate IL1B expression, ultimately promoting classical ...
Qianrang Lu   +16 more
wiley   +1 more source

Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis

open access: yesAdvanced Science, EarlyView.
Our study identifies selenium deficiency as a hallmark of MASH pathogenesis. Dietary selenium supplementation enhances hepatic fatty acid oxidation (FAO) and attenuates MASH progression by activating the PPARα pathway via selenoprotein H (SELENOH). This selenium‐SELENOH‐PPARα nexus redefines the functional scope of selenoproteins, moving from redox ...
Yuwei Zhang   +11 more
wiley   +1 more source

Remote Activation of Spinal TRPV1 by Magnetic Nanocubes Confers Cardioprotection Against Myocardial Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
Fe‐based magnetic nanocubes conjugated with TRPV1 antibodies (FeNCs‐TRPV1) are developed for the specific targeting of TRPV1 channels. Intraspinally injected FeNCs‐TRPV1 induces TRPV1 desensitization in rats exposed to repetitive and transient ACMF.
Xueying Cheng   +15 more
wiley   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy